#Efsitora
LightNews LightNews
nejm.org
Daily insulin injections can be a burden for patients with type 2 diabetes. Insulin efsitora is a new basal insulin that can be given once weekly. Research findings comparing efsitora with degludec are summarized in a new Quick Take video. youtu.be/miNU6siDB1E

#EndoSky #MedSky
Insulin Efsitora versus Degludec in Type 2 Diabetes | NEJM
YouTube video by NEJM Group
youtu.be
December 13, 2024 at 8:04 PM
medpagetoday.com
The FDA approved the once-weekly basal insulin efsitora (Onswik), drugmaker Eli Lilly announced on Thursday.
https://www.medpagetoday.com/endocrinology/diabetes/123153
FDA Approves Efsitora Weekly Insulin for Type 2 Diabetes
Approval marks the second once-weekly basal insulin for this population
www.medpagetoday.com
September 25, 2026 at 8:14 PM
redgdps.bsky.social
Nuevas Insulinas semanales en #congresoRedgdps con @GMNdoc #GelyAlvarez
#Efsitora
November 21, 2024 at 9:57 AM
nejm.org
In the QWINT-2 phase 3 trial, adults with type 2 diabetes who had not previously received insulin were assigned to receive once-weekly efsitora or once-daily degludec. Efsitora was noninferior to degludec in reducing glycated hemoglobin levels. nej.md/3Xuarje

#MedSky
The New England Journal of Medicine Insulin Efsitora versus Degludec in Type 2 Diabetes A PLAIN LANGUAGE SUMMARY Visual representation of daily insulin injections for a person with type 2 diabetes. Read the full Plain Language Summary at NEJM.org.
December 18, 2024 at 1:59 PM
Once weekly insulin seems to have similar outcomes to degludec - could help with patient compliance, but wonder what the $$$ will be #medsky

www.nejm.org/doi/full/10....
Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment | NEJM
Insulin efsitora alfa (efsitora) is a new basal insulin designed for once-weekly administration. Data on safety and efficacy have been limited to small, phase 1 or phase 2 trials. We conducted a 52...
www.nejm.org
December 17, 2024 at 12:14 AM
nejm.org
New in the December 12, 2024, issue of NEJM:

PCI in Patients Undergoing TAVI (NOTION-3 study) nej.md/3AH5WJo

Insulin Efsitora vs. Degludec in Type 2 Diabetes (QWINT-2 phase 3 trial) nej.md/3Xuarje

Bedaquiline Monotherapy in Multibacillary Leprosy nej.md/3ZQUjsn

#MedSky
Images and descriptions of what's available on NEJM.org this week
December 12, 2024 at 2:20 PM
nkov.bsky.social
www.medscape.com/viewarticle/...
FDA Approves Efsitora Once-Weekly Basal Insulin Injection
The approval adds a second long-acting, injectable option for the treatment of type 2 diabetes.
www.medscape.com
September 27, 2026 at 12:22 AM
casstee2000.bsky.social
www.medpagetoday.com/endocrinolog...
If this really works it would be fantastic
FDA Approves Efsitora Weekly Insulin for Type 2 Diabetes
Approval marks the second once-weekly basal insulin for this population
www.medpagetoday.com
September 28, 2026 at 2:20 PM
sstrumello.bsky.social
U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with Type 2 diabetes @prnewswire.bsky.social www.prnewswire.com/news-release...
U.S. Food and Drug Administration (FDA) approves Lilly's Onswik™ (insulin efsitora alfa-gobe), a once-weekly basal insulin injection treatment for adults living with type 2 diabetes
/PRNewswire/ -- Eli Lilly and Company today announced the U.S. Food and Drug Administration (FDA) approval of Onswik™ (insulin efsitora alfa-gobe), a...
www.prnewswire.com
September 24, 2026 at 5:46 PM
mdspirenews.bsky.social
💉 FDA approves once-weekly insulin for adults with type 2 diabetes.

Four phase 3 trials found insulin efsitora alfa-gobe noninferior for HbA1c reduction vs once-daily basal insulin comparators.

Read more: https://ow.ly/hMoS50ZRrx9

#Diabetes #FDA
September 25, 2026 at 2:55 PM
easdnews.bsky.social
Should everyone switch from once-daily insulins to #icodec or #efsitora?

#EASD Board Member Julia Mader lets you know who would benefit from once-weekly #insulins, discussing the latest data (#QWINT2) in this Expert Insights ep.

🎥👉https://easd-elearning.eu/Expert_Insights_14.html

#diabetes
January 22, 2025 at 10:38 AM
shihcheng.bsky.social
NEJM: A 52-week phase 3 trial finds once-weekly efsitora alfa effective for Type 2 diabetes. Adults show improvement without prior insulin use. PMID:40548694, N Engl J Med 2025, @NEJM https://doi.org/10.1056/NEJMoa2502796 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
https://doi.org/10.1056/NEJMoa2502796
No description available
doi.org
September 9, 2025 at 12:10 PM
nejm.org
In the QWINT-1 phase 3 trial, once-weekly insulin efsitora, administered in a fixed-dose regimen, was noninferior to glargine in reducing hemoglobin levels in patients with type 2 diabetes who had not previously received insulin. Full trial results and Research Summary: nej.md/4jX5R59
The New England Journal of Medicine Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes A Research Summary based on Rosenstock J et al. | 10.1056/NEJMoa2502796 | Published on June 22, 2025 Visual representations of the patients in the trial and the treatments they were assigned. Read the full Research Summary at NEJM.org.
July 27, 2025 at 1:00 PM
medicalprofref.bsky.social
Onswik, Lilly's once-weekly basal insulin, gains FDA approval. #DrugApprovals https://www.empr.com/news/fda-approves-onswik-insulin-efsitora-type-2-diabetes/
Once-Weekly Basal Insulin Onswik Approved for Type 2 Diabetes
Once-weekly basal insulin demonstrated noninferior glycemic control compared with daily basal insulins across four phase 3 QWINT trials in adults with type 2 diabetes.
www.empr.com
September 24, 2026 at 8:38 PM
nejm.org
New in the July 24, 2025, issue of NEJM:

Fixed-Dose Insulin Efsitora in Type 2 Diabetes (QWINT-1 phase 3 trial) nej.md/4jX5R59

Trastuzumab Deruxtecan in Gastric Cancer (DESTINY-Gastric04 phase 3 trial) nej.md/4k1dwjN

#MedSky
Images and descriptions of what's new on NEJM.org this week
July 24, 2025 at 1:25 PM
medicalprofref.bsky.social
Onswik, Lilly's once-weekly basal insulin, gains FDA approval. #DrugApproval https://www.empr.com/news/fda-approves-onswik-insulin-efsitora-type-2-diabetes/
Once-Weekly Basal Insulin Onswik Approved for Type 2 Diabetes
Once-weekly basal insulin demonstrated noninferior glycemic control compared with daily basal insulins across four phase 3 QWINT trials in adults with type 2 diabetes.
www.empr.com
September 24, 2026 at 7:38 PM
nejm.org
In QWINT-1 phase 3 trial, once-weekly insulin efsitora, administered in a fixed-dose regimen, was noninferior to glargine in reducing hemoglobin levels in patients with type 2 diabetes who had not previously received insulin. Full trial results: nej.md/4jX5R59

#ADASciSessions
A graph showing the least-squares mean glycated hemoglobin level over time among all eligible participants who had adhered to the trial intervention without using rescue medication (efficacy estimand), as well as the least-squares mean glycated hemoglobin level at week 52 among all eligible participants, regardless of adherence to the trial regimen or the use of rescue medication.
June 22, 2025 at 6:38 PM
rankednews.bsky.social
New type 2 diabetes jab could cut number of injections by 86 per cent: The National Institute for Health and Care Excellence (NICE) has issued final draft guidance recommending insulin efsitora alfa, a weekly treatment for type 2 diabetes. This new jab, also branded … https://ranked.news/1267708?u=b
Article image
August 20, 2026 at 6:00 AM
nejm.org
📖 Further reading 
Original Article by J. Rosenstock et al.: Weekly Fixed-Dose Insulin Efsitora in Type 2 Diabetes without Previous Insulin Therapy (QWINT-1 trial) nej.md/4jX5R59
February 15, 2026 at 5:01 PM
medpedshosp.medsky.social
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial

www.thelancet.com/journals/lan...
Once-weekly insulin efsitora alfa versus once-daily insulin degludec in adults with type 2 diabetes currently treated with basal insulin (QWINT-3): a phase 3, randomised, non-inferiority trial
Efsitora is a well tolerated and efficacious once-weekly alternative to daily basal insulin, with a reduced injection frequency, for the treatment of adults with type 2 diabetes.
www.thelancet.com
June 27, 2025 at 6:44 PM
biobonanos.bsky.social
Lilly's once-weekly insulin, efsitora alfa, met the primary endpoints in two Phase III studies that compared it with once-daily versions: investor.lilly.com/news-release...
investor.lilly.com
September 5, 2024 at 11:59 AM
anna1900.bsky.social
Efsitora alfa was tested in two phase 3 trials for 1 onDM1. one in pts w/ type 1 DM and one in those with type 2. Results presented at the European Association for the Studyof DM show that the wky injection is as effective as dly long-acting basal insulins.
December 5, 2024 at 2:49 PM
nejm.org
QWINT-1 phase 3 trial: Basal insulin is recommended for patients with type 2 diabetes that is not well controlled with noninsulin glucose-lowering agents, but daily injections can be burdensome. Research findings on weekly basal insulin are summarized in a new Quick Take video. nej.md/4f4zdhf
An illustration of trial participants with type 2 diabetes who received either once-weekly insulin efsitora alfa in a fixed-dose regimen or once-daily insulin glargine U100 with weekly sliding-scale dose adjustments
July 30, 2025 at 4:05 PM
rankednews.bsky.social
Eli Lilly: New type 2 diabetes jab could slash number of injections to one a week: The National Institute for Health and Care Excellence (Nice) has recommended a new weekly insulin treatment for type 2 diabetes, known as Onswik (insulin efsitora alfa) and manufacture… https://ranked.news/1268984?u=b
Article image
August 21, 2026 at 12:08 AM
mimsonline.bsky.social
The first once-weekly basal insulin (efsitora alfa, also known as Onswik) has been provisionally recommended by NICE for people with type II diabetes.

Read more on MIMS
buff.ly/yhyZCPB
First once-weekly insulin recommended by NICE
NICE has recommended insulin efsitora alfa for people with type II diabetes, in final draft guidance published today.
www.mims.co.uk
August 20, 2026 at 2:00 PM